232 related articles for article (PubMed ID: 22867787)
21. Bendamustine: a new look at an old drug.
Kalaycio M
Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
[TBL] [Abstract][Full Text] [Related]
22. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
24. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
25. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S
Leuk Res; 2014 Nov; 38(11):1269-77. PubMed ID: 25063524
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
27. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine for chronic lymphocytic leukemia.
Marchetti M; Barosi G; Liberato LN
N Engl J Med; 2001 Apr; 344(15):1166-7; author reply 1167-8. PubMed ID: 11302140
[No Abstract] [Full Text] [Related]
29. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G; Maloum K; Desablens B; Cazin B; Navarro M; Leblay R; Leporrier M; Jaubert J; Lepeu G; Dreyfus B; Binet JL; Travade P
N Engl J Med; 1998 May; 338(21):1506-14. PubMed ID: 9593789
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer.
Robinson P; Maase Hv; Bhalla S; Kielhorn A; Aristides M; Brown A; Tilden D
Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):27-38. PubMed ID: 19807333
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
36. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Blommestein HM; de Groot S; Aarts MJ; Vemer P; de Vries R; van Abeelen AF; Posthuma EF; Uyl-de Groot CA
Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
[TBL] [Abstract][Full Text] [Related]
38. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
Malipatil B; Ganesan P; Sundersingh S; Sagar TG
Hematol Oncol Stem Cell Ther; 2011; 4(4):157-60. PubMed ID: 22198186
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
40. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
